All Outputs (27)

A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies (2018)
Presentation / Conference
Yiu, Z., Mason, K., Barker, J., Hampton, P., McElhone, K., Smith, C., …Burden, D. (2018, August). A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies. Presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: Previous studies using incomplete trial inclusion and exclusion criteria suggest a difference between the reported effectiveness and safety of biologic therapies between randomised clinical trials (RCT) and real-world populations of patie... Read More about A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies.

THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES (2018)
Presentation / Conference
Mason, K. (2018, June). THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES. Poster presented at 5th World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden

Introduction: Whether psoriasis patients exposed to biologic therapies have an elevated risk of keratinocyte carcinoma (KC), including basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) remains uncertain. Objective:The aim of t... Read More about THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES.

Real-world use of fumaric acid esters in psoriasis: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2017)
Presentation / Conference
Mason, K. J., Lunt, M., Hunter, H. J., Jabbar-Lopez, Z. K., Kirby, B., Kleyn, C. E., …Grp, B. A. D. B. I. R. S. (2017, November). Real-world use of fumaric acid esters in psoriasis: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Paper presented at Psoriasis Gene to Clinic, 8th International Congress, The Queen Elizabeth II Conference Centre, London, UK

A real-world comparison of effectiveness and safety outcomes between clinical trial-eligible and -ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2017)
Presentation / Conference
Mason, K., Barker, J., Smith, C., Hampton, P., Lunt, M., McElhone, K., …Burden, A. (2017, November). A real-world comparison of effectiveness and safety outcomes between clinical trial-eligible and -ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Paper presented at Psoriasis Gene to Clinic, 8th International Congress, The Queen Elizabeth II Conference Centre, London, UK

Completeness of reporting of overnight hospitalisations to a psoriasis pharmacovigilance register and the National Health Service Wales Informatics Service (2017)
Presentation / Conference
Mason, K. J., Ali, H., Reynolds, N. J., Burden, A. D., Smith, C. H., Evans, I., …Griffiths, C. E. . M. (2017, August). Completeness of reporting of overnight hospitalisations to a psoriasis pharmacovigilance register and the National Health Service Wales Informatics Service. Paper presented at 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Palais de Congres de Montreal, Montreal, Canada

Background: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a longitudinal, observational, web-based pharmacovigilance register of patients with moderate-to-severe psoriasis. Patients are currently recruited from... Read More about Completeness of reporting of overnight hospitalisations to a psoriasis pharmacovigilance register and the National Health Service Wales Informatics Service.

Persistence with second-line biological therapies in patients with psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2017)
Presentation / Conference
Iskandar, I. Y. K., Warren, R., Lunt, M., Mason, K. J., Evans, I., McElhone, K., …Ashcroft, D. M. (2017, July). Persistence with second-line biological therapies in patients with psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Paper presented at The 97th Annual meeting of the British Association of Dermatologists, The Arena and Convention Centre Liverpool, Liverpool, United Kingdom

Completeness of Reporting of Basal Cell Carcinoma and Squamous Cell Carcinoma to a Pharmacovigilance Register and the Health and Social Care Information Centre (2016)
Presentation / Conference
Mason, K. J., Lunt, M., Reynolds, N. J., Ashcroft, D. M., Burden, A. . D., Ormerod, A. D., …Griffiths, C. E. . M. (2016, August). Completeness of Reporting of Basal Cell Carcinoma and Squamous Cell Carcinoma to a Pharmacovigilance Register and the Health and Social Care Information Centre. Paper presented at The Convention Centre Dublin, Dublin, Ireland

32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management